Therapeutics and Biomaterials for Musculoskeletal Disease: Global Markets: HLC086A

Therapeutics and Biomaterials for Musculoskeletal Disease: Global Markets

Report Code: HLC086A

Publish Date: Jul 2010

Publisher: BCC Publishing

Category: Health Maintenance

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for musculoskeletal disease is currently approaching $45 billion. The overall 5-year compound annual growth rate (CAGR) is forecasted to be about 5%, bringing the total market to more than $57 billion by 2014.
Rheumatoid arthritis and osteoarthritis currently represent 53% of the total market. The RA market was worth an estimated $9.5 billion in 2009 and should reach nearly $12.5 billion by 2015, while the osteoarthritis segment was valued at $14.5 billion in 2009 and should reach an estimated $19 billion by 2014. For both sectors this represents a compound annual growth rate (CAGR) of 5.6%.
Lupus is an emerging area for development, as outcome measures and understanding of the disease pathology become more refined. This segment was valued at $1.5 billion in 2009 and is projected to reach $2 billion by 2014, a compound annual growth rate (CAGR) of 5.2%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC’s goal in conducting this study was to determine the current status of the musculoskeletal disease (MSD) treatments and assess the growth potential of this area over a 5-year period from 2009 to 2014.

Our key objective was to present a comprehensive analysis of the current pipeline of therapeutics and biomaterials utilized in the treatment of MSDs, analyze the market and forecast for MSD therapeutics and treatments, and outline the key factors that will influence this therapeutic area in the next few years.

Diseases of the musculoskeletal system have plagued a significant portion of the population, and the number of incidence increases as the population ages. There have been many successful therapeutics marketed to date, but there is still room for more effective therapies. Advances in biomaterials are being translated into viable products in the orthobiologics area as well, thus changing the way a number of related disease states are treated. More is being elucidated about these diseases, and this promises to translate into more therapies and market opportunities for a variety of players.

REASONS FOR DOING THIS STUDY

Musculoskeletal disease affects roughly 20% of the population and is a significant factor in overall healthcare expenditure. Diseases such as rheumatoid arthritis, osteoporosis, and osteoarthritis are treated with various drug types, and a large development pipeline of potential new therapies is currently being tested. Clinical success has proven elusive, however, as there are now numerous companies developing novel treatments. This report reviews the programs in development and quantifies the market opportunities in MSDs. This study aims to quantify the direction in which this market is heading and the areas in which opportunities may lie.

SCOPE OF REPORT

The scope of this report focuses on the ethical pharmaceutical segment and biomaterials areas, usually categorized with medical devices. We have compiled a study of the market, as well as current and emerging modes of treatment. We present the segment economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for the time period from 2009 to 2014. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients, and the medical community. It will also be of interest also to suppliers of products and services to this market area.

INTENDED AUDIENCE

The intended audience for this report is the pharmaceutical and biotechnology diagnostics industries, as well as the medical industry that treats patients in these areas.

METHODOLOGY

BCC presents an analysis by each disease area and the number of current patients. Based on our surveys, we then analyze the potential applications for pharmaceuticals and forecast markets for 2009 and 2014.

INFORMATION SOURCES

BCC surveyed approximately 50 companies to obtain data for this study. Included were drug development and device companies and medical professionals. We also spoke with patients affected by musculoskeletal diseases. In addition, we compiled data from current financial and trade information and government sources.

ANALYST CREDENTIALS

Maura Lane Warner has more than 18 years of experience primarily in the biotechnology and pharmaceutical industries as a business development and market development executive with additional experience in operations and portfolio management.

Maura has worked at Wyeth/Genetics Institute and Shire Pharmaceuticals along with a number of venture-backed startup companies, successfully closing numerous licensing and partnership transactions and commercializing therapeutics and technology platforms.

She has a BS in Chemical Engineering and an MBA in Marketing and Finance. Maura has also authored previous reports titled Therapeutics and Diagnostics for Alzheimer’s Disease: Global Markets and Therapeutics for Memory and Cognition.

BCC ONLINE SERVICES

BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:

Examine BCC’s complete catalog of Market Research Reports and place direct orders
Subscribe to any of BCC’s many industry newsletters
Read announcements of recently published reports and newly launched newsletters
Register for BCC’s well-known conferences
Request additional information on any BCC product
Take advantage of special offers

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com

[+] Show Chapter Details

Title/Chapter Name	Pages	Member Price
Full Report: Therapeutics and Biomaterials for Musculoskeletal Disease: Global Markets	214	Free
Chapter- 1: INTRODUCTION	3	Free
STUDY GOALS AND OBJECTIVES REASONS FOR DOING THIS STUDY SCOPE OF REPORT INTENDED AUDIENCE METHODOLOGY INFORMATION SOURCES ANALYST CREDENTIALS RELATED BCC REPORTS BCC ONLINE SERVICES DISCLAIMER
Chapter- 2: SUMMARY	3	Free
Table Summary : GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL DISEASE, THROUGH 2014 Figure Summary : GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL DISEASE, 2009 AND 2014
Chapter- 3: OVERVIEW	43	Free
DEFINITION AND MARKET STRUCTURE DISEASES OF THE BONE DISEASES OF THE SKELETAL MUSCLE DISEASES OF THE JOINTS Table 1 : PROPORTION OF U.S. POPULATION REPORTING CHRONIC MEDICAL CONDITIONS Figure 1 : PROPORTION OF U.S. POPULATION REPORTING CHRONIC MEDICAL CONDITIONS
Chapter- 4: THERAPEUTICS	45	Free
DMARDS BIOLOGICS NSAIDS CORTICOSTEROIDS BISPHOSPHONATES CALCITONINS ESTROGEN REPLACEMENT THERAPY SELECTIVE ESTROGEN RECEPTOR MODULATORS PARATHYROID HORMONE ORTHOBIOLOGICS BMPS PROTEIN THERAPY GENE THERAPY CELLULAR THERAPY SYNTHETIC BONE GRAFT POLYMERS COMPOSITE GRAFTS DEMINERALIZED BONE MATRIX VISCOSUPPLEMENTATION MARKET SIZE AND KEY PLAYERS MARKET SIZE GLOBAL INDUSTRY STRUCTURE APPLICATIONS ORTHOBIOLOGICS AUTOGENOUS BONE GRAFT AND THE BONE GRAFT SUBSTITUTE MARKET MARKET CHALLENGES EXISTING MARKET AVERAGE SELLING PRICE FUTURE OF THE MARKET THERAPEUTICS SUMMARY OF COMMON MEDICATIONS Table 3 : GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 Figure 3 : GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009
Chapter- 5: LEGISLATION AND REGULATORY ENVIRONMENT	2	Free
HEALTHCARE REFORM
Chapter- 6: RELATED DEALS AND PARTNERSHIPS	4	Free
Table 27 : VENTURE INVESTMENT IN MSD COMPANIES Table 28 : RELATED DEALS AND PARTNERSHIPS
Chapter- 7: PIPELINE	7	Free
Table 29 : CLINICAL DEVELOPMENT PIPELINE
Chapter- 8: PATENT ANALYSIS	29	Free
PATENT EXPIRATIONS
Chapter- 9: C. CRAMER & CO. GMBH	76	Free
AB SCIENCE ABBOTT ABLYNX, NV ACCELERON PHARMA ACTIVE BIOTECH RESEARCH AB ALDER BIOPHARMACEUTICALS, INC. ALETHIA BIOTHERAPEUTICS INC. AMGEN INC. ARANA THERAPEUTICS ARRAY BIOPHARMA ASTELLAS ASTION PHARMA A/S ASTRAZENECA BAYER SCHERING PHARMA AG BIOGENIDEC BIOIBERICA BIOMET BIOTIE THERAPIES BMS BOEHRINGER INGELHEIM INTERNATIONAL GMBH BONE MEDICAL LTD. BTG INTERNATIONAL LTD. CAN-FITE BIOPHARMA CARTICEPT MEDICAL, INC. CELGENE CORPORATION CENTOCOR ORTHO BIOTECH CEPHALON INC. CHELSEA THERAPEUTICS INC. CHEMOCENTRYX, INC. CHUGAI COMBINATORX INC. CRYSTAL GENOMICS CYTOKINETICS DELENEX THERAPEUTICS AG ELAN ELI LILLY ESBATECH EUROFARMA LABS FERRING PHARMA FOREST LABS GENELABS TECHNOLOGIES (GSK) GENENTECH, INC. GENMAB A/S GENZYME GLAXO WELLCOME U.K. LTD. (GSK) HALOZYME THERAPEUTICS HARBOR BIOSCIENCES, INC. (FORMERLY HOLLIS-EDEN) HORIZON THERAPEUTICS HUMAN GENOME SCIENCES HUMANIS KLINIKUM IDERA PHARMACEUTICALS IMMUNOMEDICS, INC. IMMUPHARMA, PLC INCYTE IPSEN ISOTIS ORTHOBIOLOGICS (ACQUIRED BY INTEGRA LIFESCIENCES) ITALFARMACO S.P.A. JOHNSON & JOHNSON SERVICES INC. KENSEY NASH LEXICON PHARMACEUTICALS MEDAREX MEDIGENE AG MEDIMMUNE LLC. MEDIPOST CO. LTD. MEDIVIR AB MEDTRONIC SOFAMOR DANEK MERCK MERRIMACK PHARMACEUTICALS MERRION PHARMACEUTICALS LTD. MITSUBISHI TANABE MORPHOSYS AG NEOVACS SA NICOX SA NIPPON KAYAKU NORDIC BIOSCIENCE A/S NOVARTIS AG NOVO NORDISK A/S NOXXON PHARMA AG NPS PHARMACEUTICALS NUON THERAPEUTICS INC. NUVO RESEARCH INC. NYCOMED ONO PHARMA ORTHOVITA OSTEOLOGIX INC. OSTEOTECH PALAU PHARMA PANGENETICS BV PASCOE PHARMA PDL BIOPHARMA INC. PFIZER INC. PHYTOHEALTH CORPORATION POZEN INC. RADIUS HEALTH REGENERON RIGEL PHARMA INC. RIVEX PHARMA INC. F. HOFFMANN-LA ROCHE LTD. SANOFI-AVENTIS SERVIER SMITH & NEPHEW PLC SPINAL RESTORATION INC. STRYKER BIOTECH SUCAMPO PHARMACEUTICALS INC. SYNTHES INC. TAKEDA TEVA TRUBION PHARMACEUTICALS INC. UCB UNIGENE LABS VERTO MEDICAL LTD. WRIGHT MEDICAL TECHNOLOGY INC. XOMA ZELOS THERAPEUTICS INC. ZIMMER ZOSANO PHARMA ZYMOGENETICS INC.
Chapter- 10: OUTLOOK-TRENDS AND CHALLENGES	2	Free
MSDS ARE A LARGE BURDEN ON THE HEALTHCARE SYSTEM OUTLOOK FOR ORTHOBIOLOGICS IS BRIGHT OSTEOPOROSIS: PAYER ACCEPTANCE IS KEY ISSUE COMPETITION FOR THE RA PATIENT POPULATION FAILING ANTI-TNF THERAPIES LUPUS IS A CHALLENGING INDICATION DIAGNOSIS RATES FOR PSORIATIC ARTHRITIS AND AS

Recent Reports
Top Trending Reports

Related Reports

Recent Reports

Surgical Equipment: Technologies and Global Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - HLC154C

The global market for surgical equipment and technologies was valued at $37.6 billion in 2023. This market is expected to grow from $40.0 billion in 2024 to $56.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2029.

Conventional and Alternative Pain Treatment Markets

Published - Nov 2024 | Publisher - Partha Sarathi Das | Code - HLC266B

The global market for conventional and alternative pain treatment is expected to grow from $96.2 billion in 2024 and is projected to reach $144.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029.

CRISPR Technology: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC258C

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC239C

The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.

Medical Devices: Technologies and Global Markets

Published - Oct 2024 | Publisher - Partha Sarathi Das | Code - HLC170F

The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Top Trending Reports

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Medical Devices Industry: Competitive Landscape

Published - Nov 2024 | Publisher - BCC Publishing | Code - MDS010C

The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC239C

FAQ

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More

Therapeutics and Biomaterials for Musculoskeletal Disease: Global Markets

Report Highlights

Table of Contents

Related Reports

Recent Reports

Top Trending Reports

Become A Member

Custom Consulting

Scorecard

Innovation Spotlight